30 closest matches · ranked by relevance
Sickle Cell Disease
Primary: Percentage of Participants With Event-Free Survival (EFS) — 76; 69 percentage of participants
Sickle Cell Disease
Primary: Number of Emergency Department (ED)/Acute Care Visits — 0; 1 number of visits
Anemia, Sickle Cell
Primary: Wechsler Adult Intelligence Scale (WAIS)-III Performance IQ — 90.6; 95.9 Points on a scale — p=0.008
Sickle Cell Disease
Primary: Number of Participants With Graft Failure — 3 Participants
Sickle Cell Disease
Primary: Dose Limiting Toxicities as a Measure of Whether Infusional Lexiscan is Safe in Individuals With SCD. — 1; 0; 0; 0 number of DLT
Sickle Cell Disease
Primary: Number Participants With Most Common Reported Drug Related Adverse Events — 6; 3; 3 Participants
Sickle Cell Disease · Sickle Cell Anemia · Hemoglobin SS
Primary: Acceptability of Decision Aid Education Assessed by the Acceptability Survey — 3; 3; 3; 3 units on a scale
Anemia, Sickle Cell
Primary: Gardos Channel Activity — -0.0342; 0.0043; 0.1076 mmol/10^13 cells x min — p=0.080
Sickle Cell Disease · Sickle Cell Anemia
Primary: Mean Red Blood Cells Lifespan in Participants — 64.1; 113.4; 126.0; 123.7 day — p=<0.001
Sickle Cell Disease
Primary: SCD-specific Knowledge — 32.0; 32.0; 33.5; 33 score on a scale
Sickle Cell Disease · Sickle Cell Anemia
Primary: Microvascular Blood Flow Rate Change — 1.09; 0.86 Ratio of change
Sickle Cell Disease
Primary: Mean Change in the Plasma Soluble P-selectin Level — 0.74; 0.10 ng/ml — p=0.64
Sickle Cell Disease · Vaso-occlusive Crisis
Primary: Change in D-dimer — 478.8; 260.1 ng/mL
Sickle Cell Disease · Sickle Cell Trait · Beta-Thalassemia
Primary: Sensitivity, Specificity, Positive Predictive Value and Negative Predictive Value — 96.6; 100; 0; 91.3 percentage
Sickle Cell Disease
Primary: Number of Participants With Sufficient Collection of Hemopoietic Stem Cells (HSCs) Without Serious Adverse Events — 14 Participants
Sickle Cell Disease
Primary: Overall Incidence of Treatment Emergent Severe Adverse Events (SAE) — 15; 20 Participants — p=0.19
Sickle Cell Disease
Primary: MRI Parameter - LVEDVi, mL/cm2 (Measured Using Method of Disks, Controls Serve as Normal Ranges) — 124.0; 78.7 mL/cm2 — p=0.0039
Sickle Cell Disease
Primary: Fetal Hemoglobin Level — 8.3 Percentage
Anemia, Sickle Cell
Primary: Change in Qualitative Spleen Function From Randomized Control Trial Baseline Measurement - Compared Between Children Randomized to Hydroxyurea vs Placebo — 16; 15; 44…
Sickle Cell Trait
Primary: Acceptability — 11; 8; 11; 8 Participants
Sickle Cell Disease (SCD)
Primary: Number of Participants With Treatment Emergent Serious Adverse Events (SAEs) — 3; 3 Participants
Sickle Cell Disease
Primary: Number Of Participants With Treatment-emergent Adverse Events (TEAEs) And Serious Adverse Events (SAEs) — 12; 24; 18; 23 Participants
Sickle Cell Disease
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 1; 3; 1; 0 Participants
Neutropenia · Sickle Cell Disease
Primary: The Percentage Change in HbF Level From Baseline to the Average Over the Final 1 Month of Study. — 1; 1; 6 Participants
Sickle Cell Disease
Primary: % of Patient-years With Malignancies — 0.001 % patient-years
Sickle Cell Disease · COVID-19
Primary: Antibody Response to COVID-19 Vaccine in Persons With Sickle Cell Disease — 32.155 units per mL
Sickle Cell Disease
Primary: Percentage of Participants With Two-Year Post-Transplant Event Free Survival (EFS) — 88.0; 79.3 Percentage of Participants
Sickle Cell Disease
Primary: SS RBC Adhesion (Epi -1d/cm2- vs. Sham) by Treatment — 0; -0.3; 7.4; 2.7 Percentage of total RBC
Sickle Cell Disease
Primary: Number of Participants With Adverse Events — 4 Participants
Sickle Cell Disease
Primary: Level of Satisfaction on SCD Current Treatment and Management — 4.12 score on a scale